

Case study

HIGH DEGREE ATRIOVENTRICULAR BLOCK:First Presentation of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia

ABSTRACT

Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is an uncommon inherited cardiac disease characterized by progressive right ventricular (RV) dysfunction due to fibro-fatty replacement of the myocardium and associated with high risk of ventricular arrhythmias and sudden cardiac death. ARVC/D has a predominantly autosomal dominant inheritance, although recessive forms associated with a cutaneous phenotype, such as Naxos disease and Carvajal syndrome, are also observed. **The golden** standard for diagnosing ARVC/D is an endomyocardial biopsy demonstrating fibro-fatty replacement. Our case concerns a young adult patient with rare bradyarrhythmias (type high degree atrioventricular block) associated with signs and symptoms of right heart failure who was diagnosed with arrhythmogenic right ventricular cardiomyopathy ARVC with **pejorative prognosis shortly died after** admission.

KEYWORDS: High degree atrioventricular block, arrhythmogenic right ventricular cardiomyopathy/dysplasia, Task force criteria

INTRODUCTION

Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is characterized by progressive replacement of myocardial cells by fibro-fatty tissue, initially only in the right ventricle, but it may **extent** to the left **ventricle as well** [1]. **The diagnosis is made with the Task Force Criteria** [1]. The estimated prevalence is 1:5,000 individuals [2]. Genetic alterations underlying ARVC are often mutations in one of the cardiac desmosome genes [3]. These mutations are known for their phenotype diversity within families [4]. **The golden** standard for diagnosing ARVC/D is an endomyocardial biopsy demonstrating fibro-fatty replacement [5]. ARVC is associated with ventricular tachyarrhythmias giving rise to syncope or sudden cardiac death. However, we present a young adult patient with bradyarrhythmias (type high degree atrioventricular block) who was diagnosed with arrhythmogenic right ventricular cardiomyopathy **ARVC shortly died after** admission.

Comment [dvk1]: This whole sentence has been taken verbatim from the article

CLINICAL PRESENTATION

A 51-year-old patient with no particular medical history, admitted at the cardiology emergency department for a repetitive episode of syncope associated with aggravating effort dyspnea. At admission, patient was dyspneic stage 3 of the NYHA scale, with no chest pain or palpitation, associated with episodes of syncope. Blood pressure (BP) at 110/60 mmHg, and heart rate (HR) of 40 beats per minute (bpm) associated with signs of right heart failure (edema of the lower limbs, Turgor of the jugular veins, effort hepatalgia).

The electrocardiogram (ECG) findings showed a complete atrioventricular block with an escape rhythm of 40 bpm (Figure 1) associated with a completely right bundle block (RBB).




Figure 1: Electrocardiogram (ECG): 3rd degree atrioventricular block, escape rhythm 40bpm associated with RBB.

Transthoracic echocardiography (TTE) performed on the patient showed a non-dilated left ventricle (LV) with a LVEF of 30% measured by bipolar Simpson method, and a very dilated right ventricle (Basal diameter of the right ventricle = 51mm). A dyskinetic free wall of the right ventricle was observed associated with an aneurysm, and multiple trabeculations, in severe dysfunction. We also note a functional laminar tricuspid regurgitation (TR) due to dilation of the tricuspid ring and coaptation defect (Figure 2).

Comment [dvk2]: This para could be modified as 51 year old male patient who was apparently asymptomatic till Months back presented to the emergency department with progressive dyspnea on exertion NYHA class III and repetitive post exertional syncope. On examination

Comment [dvk3]: ECG quality is suboptimal and preferably a 12 lead ECG is required




Figure 2a: Transthoracic echocardiography (TTE): 4 chambers apical view: showing very dilated right ventricle with an aneurysm, and multiple trabeculations, in severe dysfunction (yellow arrow).

Figure 2b: TTE: Doppler: 4 chambers apical view: functional laminar tricuspid regurgitation (TR) [red arrow] and medium abundance pericardial effusion.




Figure 2c: TTE: 4 chambers apical view: presence of spontaneous contrast and thrombus intratrabeculae (blue arrow) with dilated left atrium.

The biological assessment showed an increased level of NT Pro BNP (NT Pro BNP: 1000 ng/l) in the blood with a slightly increased in the level of heart enzyme troponin (Highly sensitive troponin = 70 ng/l).

Faced with this clinical outcome, a cardiac magnetic resonance imaging (cMRI) was performed urgently, objectifying a dilated and severe right ventricle (RV) dysfunction. A global RV hypokinesia with an indexed right ventricle tele diastolic volume (RV DTV) of 192ml/m^2 and a 21% ejection fraction of the right ventricle (EFRV) Figure 3.




Figure 3: Cardiac MRI: cross section showing a dilated right ventricle with an impaired ejection fraction of 21%.

cMRI also identified multiple aneurysms and trabeculations located at the level of the RV which interest its free wall (Figure 4) and the infundibulum of pulmonary artery. The right atrium (RA) was also dilated (Index volume of the right atrium = 90ml/m^2), with the presence of a thrombus at the bottom level of the RA measuring $14\text{mm} \times 10\text{mm}$ in diameter. Hypertrophy of the RV wall (figure 5).




Figure 4: Cardiac MRI: T2 **sequency**: Hypertrophy of the right ventricle with multiple aneurysms of its free wall, presence of medium pericardial effusion.



Figure 5: Cardiac MRI: Thrombus at the bottom of the right atrium associated with a dilated right ventricle without late enhancement.

The LV was non-dilated, non-hypertrophied (indexed LV tele diastolic volume= 62ml/m^2 and tele systolic volume= 45.3ml/m^2) with a severe impaired global function. Pericardial effusion of medium abundance in circumference associated medium bilateral pleural effusion with no remarkable fibrose tissue.

This cardiac finding confirmed the diagnosis of arrhythmogenic right ventricular cardiomyopathy.

The patient was subsequently rushed to cath lab for coronary artery angiography and pacemaker, but the evolution was rapidly fatal, progressing to death after an extreme bradyarrhythmia and asystole.

DISCUSSION

In this case report, we describe an adult patient with a symptomatic high degree atrioventricular conduction block before ARVC became overt. He presented with a coincidentally found third degree atrioventricular block type after episodes of syncope, which the transthoracic echocardiography (TTE) suspected an ARVC confirmed by cardiac MRI.

Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is an uncommon inherited cardiac disease characterized by progressive right ventricular (RV) dysfunction due to fibro-fatty replacement of the myocardium and associated with high risk of ventricular arrhythmias and sudden cardiac death [6]. ARVC/D has a predominantly autosomal dominant inheritance, although recessive forms associated with a cutaneous phenotype, such as Naxos disease and Carvajal syndrome, are also observed [7]. A cross-sectional study aimed to assess the prevalence and clinical significance of bradyarrhythmias in ARVC was carried out by Erpang Liang et al. from May 1995 to December 2017 [8] showed that bradyarrhythmias were commonly seen in ARVC, and intraventricular conduction block (ICB) was the most common type. In our case AV block was the first clinical presentation.

Classically, ARVC/D usually presents between the second and fourth decades of life with syncope, symptomatic arrhythmias, or sudden cardiac death (SCD) [9]. In our case, patient consulted for repetitive episodes of syncope and heart failure (HF) symptoms who later died before few hours before cardiac intervention. These symptoms were all combined in our patients who had a pejorative prognosis. A study reports that HF hospitalization has a significant relation with malignant clinical course in ARVC patients, and first-degree AVB at baseline is strongly associated with HF hospitalization [10].

There is no single diagnostic test for ARVC/D. The diagnosis is made based on major and minor clinical, electrical, and imaging criteria that have been devised by expert consensus of the Task Force Criteria (TFC) originally proposed in 1994 and further revised in 2010 [1,6]. The diagnosis was certain with major and

minor criteria confirming the **diagnostic**. TTE **et** cardiac MRI play an important role in diagnosis confirmation as well as deferential diagnosis of ARVC/D [10].

The American College of Cardiology, the American Heart Association and the European Society **and** Cardiology recommended ICDimplantation for the prevention of SCD events [11]. Risk stratification and indication **to** ICDimplantation in ARVC/D has been proposedby an international task force consensus statement [12]. **Individuals who present with** congestive heart failure are managedwith diuretics and angiotensin-converting enzyme (ACE) inhibitors or aldosterone inhibitors, with heart transplantation considered in terminal stages of the disease. **Anticoagulation** may be used in ARVC/D patients with large, hypokinetic RV and slow blood flowbecause of the risk of thrombosis [13].Therapy with beta blockers, sotalolor amiodaronemay be effective in suppressingventricular arrhythmias and possibly in preventing sudden cardiac death [14]. Management of family members of patients with ARVC/D is complex due to the incomplete penetranceand variable expressivity nature of the disease [15]. In our case screening of family members was **difficult as patient** was from another region. Atrioventricular conduction abnormalities have only rarely been described in patients already diagnosedwith ARVC [16]. Our patient presented both symptoms of **bradyarrhythmias** and heart failure is **rare entity as** heart failure signs a rarely neglected.

CONCLUSION

ARVC/D is an inherited disease characterized by fibro-fatty replacement of the right ventricular myocardium, which significantlyincreases the risk ofparoxysmal ventricular arrhythmias and SCD. Diagnosis is based on the 2010 modified Task Force criteria, **requiring**clinical and family history,electrocardiography, and imaging. Diagnosis may be confirmed byendomyocardial biopsy. This case report **confirms ARVC/D** can appear as conduction disorder and heart failure **increase** the risk of **mortality**.

Comment [dvk4]: Conclusion needs to be rewritten to summarise the case report properly

ETHICAL APPROVAL

As per international standard or university standard written ethical approval has been collected and preserved by the author(s).

CONSENT

As per international standard or university standard, patient(s) written consent has been collected and preserved by the author(s).

REFERENCES

1. Danielle E Burghouwt, Janneke AE Kammeraad, Paul Knops, Frederik A du Plessis, Natasja MS de Groot. Bradyarrhythmias: First Presentation of Arrhythmogenic Right Ventricular Cardiomyopathy? *J Clin Med Res.* 2015; 7:278-281.
2. Hamilton RM, Fidler L. Right ventricular cardiomyopathy in the young: an emerging challenge. *Heart Rhythm.* 2009;6:571-575.
3. Den Haan AD, Tan BY, Zikusoka MN, Llado LI, Jain R, Daly A, Tichnell C, et al. Comprehensive desmosome mutation analysis in north americans with arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Circ Cardiovasc Genet.* 2009 ;2:428-435.
4. Quarta G, Muir A, Pantazis A, Syrris P, Gehmlich K, Garcia-Pavia P, Ward D, et al. Familial evaluation in arrhythmogenic right ventricular cardiomyopathy: impact of genetics and revised task force criteria. *Circulation.* 2011;123 n:2701-2709.
5. Peters S, Trummel M, Koehler B, Westermann KU. Mechanisms of syncope in arrhythmogenic right ventricular dysplasia-cardiomyopathy beyond monomorphic ventricular tachycardia. *Int J Cardiol.* 2006;106:52-54.
6. Ka Hou Christien Li, George Bazoukis, Tong Liu, Guangping Li, William K K Wu, Sunny Hei Wong, Wing Tak Wong, Yat Sun Chan, Martin C S Wong, Katharina Wassilew, Vassilios S Vassiliou, Gary Tse. Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) in clinical practice *J Arrhythm* 2017 : 21 ;34 :11-22.
7. Sultan FA, Ahmed MA, Miller J, Selvanayagam JB. Arrhythmogenic right ventricular cardiomyopathy with biventricular involvement and heart failure in a 9-year old girl. *J Saudi Heart Assoc.* 2017;29:139-42.
8. Erpeng Liang, Lingmin Wu, Siyang Fan, Xiaofei Li, Feng Hu, Lihui Zheng, Xiaohan Fan, Gang Chen, Ligang Ding, Yan Yao. Bradyarrhythmias in Arrhythmogenic Right Ventricular Cardiomyopathy *Am J Cardiol* 2019 May 15;123 :1690-1695.
9. Julia H. Indik and Frank I. Marcus. Arrhythmogenic Right Ventricular Cardiomyopathy /Dysplasia. *Indian pacing and electrophysiology journal.* www.ipej.org.
10. Kimura Y, Noda T, Matsuyama TA, Otsuka Y, Kamakura T, Wada M, Ishibashi K, Inoue Y, Miyamoto K, Okamura H, Nagase S, Aiba T, Kamakura S, Noguchi T, Anzai T, Satomi K, Wada Y, Ohno S, Horie M, Shimizu W, Yasuda

S, Shimokawa H, Kusano K. Heart failure in patients with arrhythmogenic right ventricular cardiomyopathy: What are the risk factors? *Int J Cardiol.* 2017; 241 :288-294.

11. Schinkel AF. Implantable cardioverter defibrillators in arrhythmogenic right ventricular dysplasia/cardiomyopathy: patient outcomes, incidence of appropriate and inappropriate interventions, and complications. *Circ Arrhythm Electrophysiol.* 2013;6:562–8.

12. Corrado D, Wichter T, Link MS, et al. Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement. *Eur Heart J.* 2015;36 :3227–37.

13. Wlodarska EK, Wozniak O, Konka M, Rydlewska-Sadowska W, Biederman A, Hoffman P. Thromboembolic complications in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Europace.* 2006;8 :596–600.

14. Danielle E Burghouwt, Janneke AE Kammeraad, Paul Knops, Frederik A du Plessis, Natasja MS de Groot. Bradyarrhythmias: First Presentation of Arrhythmogenic Right Ventricular Cardiomyopathy? *J Clin Med Res.* 2015;7:278-281.

15. Kirubakaran S, Bisceglia C, Silberbauer J, et al. Characterization of the arrhythmogenic substrate in patients with arrhythmogenic right ventricular cardiomyopathy undergoing ventricular tachycardia ablation. *Europace.* 2017;19:1049–62.

16. Pu JL, Wang HT, Liu TK, Ma KJ, Li N, Yao Y, Chu JM, et al. [Clinical and ECG features of arrhythmogenic right ventricular cardiomyopathy: a retrospective analysis of 31 cases]. *Zhonghua Xin Xue Guan Bing Za Zhi.* 2007;35:24-27.